Though lymphoproliferative diseases during pregnancy can lead to complications, a host of treatment options exists.
HIV-induced regulatory B cells may inhibit T cell function through multiple mechanisms, potentially driving lymphomagenesis.
Risk for malignancy was increased in patients who underwent 2 or 3 lines of treatment compared with patients who only underwent 1 line of treatment.
The investigational treatment was associated with a high rate of neurotoxicity.
Further investigations should look at the role of acquired BCL2 mutations in venetoclax resistance.
Severe fatigue was more common in NHL survivors compared with the general population.
Patients who achieved event-free survival at 24 months following diagnosis were evaluated for late relapses.
The model stratified patients into 3 risk groups based on median time to disease progression.
The risk of breast implant-associated anaplastic large cell lymphoma may be higher than previously reported for women who receive textured implants, according to researchers.
In a review, researchers discussed the value of combining immunotherapy, targeted therapy, and chemotherapy to improve treatment for double hit lymphoma.
Early failure after treatment, old age, and treatment regimens not including stem cell transplantation were associated with poorer survival.
With numerous options, there is growing debate over the frontline treatment of Hodgkin lymphoma.
Though the primary survival endpoints were not met in this study, younger patients experienced improved outcomes with ibrutinib.
Treatment for early-stage pediatric HL can include chemotherapy with or without radiotherapy, although use of radiotherapy is waning.
Patients with higher International Prognostic Index scores or advanced-stage disease experienced improved survival when treated with ASCT.
Patients with follicular or marginal zone lymphoma who received lenalidomide with rituximab experienced a median progression-free survival of 39.4 months.
The presence of rheumatologic conditions was also associated with variations in cancer site for both diffuse large B-cell lymphoma and marginal zone lymphoma.
Treatment for lymphoblastic lymphomas may result in high morbidity and poor prognosis, highlighting the need for novel targeted therapeutic approaches.
An expert panel reviewed current literature surrounding lymphoma treatment to identify and address any gaps in knowledge.
Presence of multiple mucosal sites at presentation in extranodal marginal zone lymphomas may predict poor survival outcomes.
The combination of pentostatin, cyclophosphamide, and rituximab yielded comparable rates of survival and adverse events to other combination regimens.
Ofatumumab was well tolerated by patients with advanced-stage follicular lymphoma but did not appear superior to other monotherapy agents for this disease.
Results from a phase 1 trial suggested that patients with previously treated mantle cell lymphoma may respond positively to ibrutinib plus palbociclib.
The US FDA provided updated information to women with breast implants and their health care providers on the risk of developing a specific type of lymphoma.
Researchers combined the International Prognostic Index with cell-of-origin subtype to identify patients at high risk for central nervous system relapse.
Changes to the WHO-EORTC classification for primary cutaneous lymphomas were highlighted in a recent review article.
Patients with MYC-rearranged aggressive diffuse large B-cell lymphoma appeared to achieve durable remission with EPOCH-R.
A doublet immunotherapy regimen incorporating the investigational mAb Hu5F9-G4 shows clinical activity in patients with relapsed/refractory non-Hodgkin lymphoma.
“CD19 CAR therapy has paved the way for a new field of medicine based on the genetic instruction of T-cell responses,” according to Dr Michel Sadelin.
Patients who received combined systemic and intraocular treatment had longer failure-free and relapse-free survival.
Over half of evaluable patients who received an infusion of tisagenlecleucel achieved partial or complete response.
A lack of research focusing primarily on older patients with Hodgkin lymphoma has led to an unmet need for effective, less toxic treatment in this population.
The FDA approval was supported by clinical data describing structural and functional characterization, preclinical data, human pharmacokinetic data, clinical immunogenicity data, and other data which showed no clinically meaningful differences between Truxima and Rituxan.
The approval was based on data from a randomized, double-blind, double-dummy, actively controlled trial (ECHELON-2) involving 452 patients with certain PTCLs.
Though the majority of patients with cutaneous T cell lymphomas experience pruritus, the pathophysiology of the symptom is relatively unclear.
Novel molecular technologies for detecting minimal residual disease may offer prognostic value for patients with indolent lymphomas.
Preemptive nucleos(t)ide analog treatment (NAT) was associated with decreased risk of HBV reactivation in patients receiving immunochemotherapy.
Researchers analyzed long-term follow-up data from 2 clinical trials conducted by the German Hodgkin Study Group.
Patients with peripheral T-cell lymphomas have a median overall survival of approximately 6 months.
Conflicting findings regarding the association between plasma Epstein-Barr virus load in PLWHIV and HIV-related lymphomas shows a need for assessment of who benefits from an optimal management of HIV infection and comorbidities.
The current approach to PMBCL diagnosis is not optimal due to the possibility of diagnostic inaccuracy.
Though osteonecrosis has been previously studied in childhood ALL, it has not been evaluated as a side effect of treatment for Hodgkin lymphoma.
Sequential dosing of brentuximab vedotin before and after standard doxorubicin, vinblastine, and dacarbazine showed a survival benefit in a phase II trial.
The safety and efficacy of investigational agent zanubrutinib is being evaluated in a head-to-head phase 3 trial in Waldenström macroglobulinemia.
Baseline ctDNA levels and, separately, measures of molecular response, were prognostic for outcome in patients with diffuse large B-cell lymphoma.
A retrospective study evaluated the efficacy vs pulmonary toxicity of brentuximab vedotin for relapsed or refractory Hodgkin lymphoma in pediatric patients.
A retrospective analysis of outcomes demonstrated the influence of rituximab maintenance after R-CHOP or R-CVP for follicular lymphoma in elderly patients.
Outcomes data demonstrated the impact of socioeconomic status and insurance coverage on outcomes for patients with follicular lymphoma by age (younger than 65 and 65 and older).
Signal strength of the receptors used to create CAR-T therapies in lymphoma varied depending on the signaling domain chosen for each investigational construct.
Rituximab plus lenalidomide immunotherapy may be an effective alternative to chemotherapy for patients with follicular lymphoma.
Researchers sought to determine if the newly formed regimen RiBVD was effective and tolerable in patients older than 65 with mantle cell lymphoma.